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Abstract
Background: Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a 
reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery 
since many cells cross-communicate through the secretion of soluble proteins into blood.
Methods: Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by 
using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples 
used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT 
labeling. Several proteins showing differential abundance level were selected based on literature searches and their 
specificity to the commercially available antibodies, and then verified by immunoblot assays.
Results: A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed 
abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We 
chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four 
proteins, α1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 
3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients 
and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma 
(Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The 
area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and 
progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels.
Conclusions: Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer.
Background
Breast cancer is one of the most common cancers in women
worldwide [1]. Early detection and treatment of breast can-
cer in patients showed good prognosis, but current diagnos-
tic techniques such as mammography, MRI and PET are not
sufficient to detect early stages of breast cancer efficiently
[2]. Finding a series of relevant biological markers for early
cancer detection and diagnosis and monitoring the thera-
peutic response can definitely improve our ability to man-
age breast cancer [3-5].
An emerging issue of proteomics is to discover novel bio-
logical markers that can be applied to early detection, dis-
ease diagnosis and prediction of response to therapy [6].
Proteomics has advanced direct profiling of differentially
expressed proteins between diseased and control samples,
or at various stages of diseases under particular environ-
ments [7], and thus become a key technology in biomarker
development pipeline. The biomarker pipeline can be
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divided into four phases: discovery, qualification, verifica-
tion and validation phases [8]. Discovery phase is an unbi-
ased and semiquantitative process, usually comprising
simple binary comparisons between diseased and normal
state. Tissues, body fluids, or even model cell lines are
being utilized as proteome sources. The 'products' of the
discovery phase are confirmed in the next qualification
phase. Immunoassays with commercially available antibod-
ies can be used. In verification phase, the analysis is
extended to a larger number of samples, now incorporating
a broader range of cases and controls. Although any pro-
teome source can be used in the discovery phase, biomark-
ers that are detected and validated in specimens obtained by
less invasive techniques, such as plasma or serum, are more
desirable [8,9]. The blood serum or plasma contains enor-
mous complexity of biological components which reflect
spatio-temperal changes of diseased cells, tissues, or organs
[10]. Knowing any change in the containment of blood
caused by a specific disease like cancer will help us under-
stand and develop detection and further management of the
disease.
The objective of our study is to discover new breast can-
cer biomarkers using blood plasma as proteome sources.
We previously analyzed breast cancer tissues [11] and
secretome from a breast cancer cell line [12] to detect can-
cer-relevant proteins as potential biomarkers. In the current
study, we analyzed plasma proteomes using an isotope-
coded affinity tagging (ICAT) technique. This method has
been developed to analyze relative amounts of cysteine-
containing peptides in tryptic digests of protein extracts
[6,13]. All the plasma samples used were depleted of six
high-abundance plasma proteins by affinity chromatogra-
phy. The biomarker candidates discovered were then con-
firmed and verified with pooled or individual samples, and
further with a blinded set of multiple samples by Western
blot assays. The employed ICAT and Western blot assay
strategy enabled us to identify and quantify biotinidase
(BTD) as a potential breast cancer biomarker in plasma.
Methods
Subjects
Blood samples were collected from breast cancer patients
and normal healthy volunteers at the Seoul National Uni-
versity Hospital (Seoul, Korea). The use of human samples
for research purpose was authorized by the Institutional
Review Board of Seoul National University Hospital, and
all the patients and volunteers agreed to take part in the
experiment with the name signed on the informed consent
document. The plasma sample was depleted of top six
abundant serum proteins using a multiple-affinity MARS
column (Agilent Technologies, Palo Alto, CA, USA) [12],
and precipitated with trichloroacetic acid. The pellet was
dissolved in ICAT denaturation buffer (6 M urea, 0.05%
SDS, 5 mM EDTA, 50 mM Tris-HCl, pH 8.3).
ICAT labeling and sample preparation
A pooled plasma sample from 6 breast cancer patients was
labeled with a 'heavy (H)' ICAT reagent (Applied Biosys-
tems, Framingham, MA, USA), whilst another pooled sam-
ple from 6 normal healthy women was labeled with a 'light
(L)' reagent. We pooled equal amount of proteins from indi-
vidual samples. Proteins (100 μg) in the denaturantion buf-
fer were first reduced with 250 mM tris(2-
carboxyethyl)phosphine for 30 min. ICAT-labeling was
then performed using 350 nmol ICAT reagent with gentle
shaking for 2 hr at 37°C, and terminated with 1.75 μmol
DTT for additional 5 min. The H- and L-ICAT-labeled sam-
ples were mixed, diluted 10 fold with 50 mM Tris (pH 8.0),
and digested with 5 μg of trypsin (Promega, Madison, WI,
USA) for 16 hr at 37°C. The reaction was quenched at 0.5%
phosphoric acid. The tryptic digest was applied on a poly-
sulfoethyl A column (Western Analytical, Murrieta, CA,
USA) equilibrated with 10 mM KH2PO4 in 25% ACN (pH
3.0) using an ÄKTA Explorer system (GE Healthcare Bio-
sciences, Uppsala, Sweden), eluted with a 40-min gradient
from zero to 0.4 M KCl, and collected on 40 fractions. The
SCX fractions were neutralized by the addition of 10 vol-
umes of 2× PBS, loaded on an ICATR  avidin-catridge
(Applied Biosystems), and then washed with PBS followed
by 50 mM ammonium bicarbonate in 20% methanol, pH
8.3. ICAT-labeled peptides were eluted with a solution of
0.4% TFA in 30% acetonitrile, dried in vacuo, redissolved
in 90 μl of 95% TFA, incubated at 37°C for 2 hr to cleave
off the biotin moiety from the ICAT label, and finally dried
again.
Liquid chromatography and tandem mass spectrometry
An Agilent nanoflow-1200 series HPLC system was con-
nected to a linear ion trap mass spectrometer (LTQ, Thermo
Electron, San Jose, CA, USA). The dried ICAT-labeled pep-
tide sample was reconstituted with 20 μL of 0.4% acetic
acid, and an aliquot (1 μL) was injected to a reverse-phase
Magic C18aq column (13 cm × 75 μm) equilibrated with
95% buffer A (0.1% formic acid in H2O) + 5% buffer B
(0.1% formic acid in acetonitrile). The peptides were eluted
in a linear gradient of 10 to 40% acetonitrile over 75 min.
The MS survey was scanned from 300 to 2000 m/z, and fol-
lowed by three data-dependent MS/MS scans with the fol-
lowing options: isolation width, 1.5 m/z; normalized
collision energy, 25%; dynamic exclusion duration, 180
sec.
Database searches
Peak lists were generated using Extract-msn program in
Bioworks package v3.1 (Thermo Electron) with the follow-
ing parameters: minimum ion count threshold, 15; mini-
mum intensity, 100. The peak lists were compared against
the human International Protein Index database including
known contaminants (IPI, versions 3.24, European Bioin-Kang et al. BMC Cancer 2010, 10:114
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formatics Institute, http://www.ebi.ac.uk/IPI) using the
SEQUEST (TurboSequest version 27, revision 12) allowing
two missed cleavages (trypsin) and ±0.5 and ±3 Da mass
tolerance for MS/MS and MS respectively. ICAT option
(+227.26 Da fixed modification plus +9 Da variable modi-
fication) on cysteine residue was used and a variable modi-
fication of methionine oxidation (+16 Da) was allowed.
Peptide assignment and quantification were performed with
the Trans-Proteomic Pipeline provided by Institute for Sys-
tems Biology (TPP, version 4.0, http://www.proteomecen-
ter.org). The SEQUEST search output was used as an input
for Peptide-Prophet module and peptides with probabilities
greater than 0.05 were included in the following Protein-
Prophet. Proteins with probabilities greater than 0.5 were
put into manual inspection to evaluate MS/MS spectral
quality [14]. False discovery rate was 10% at the cut-off
value of 0.5 before manual inspection. From a list of 238
proteins, 30 proteins were removed due to lack of quantifi-
cation information and 53 proteins were removed due to
their unreliable mass spectra during manual inspection. The
number of removed proteins (53 ea) by manual inspection
exceeded the number of estimated false positives (~24 ea).
As a result, the false discovery rate for the final data set
containing 155 proteins would be almost zero.
Western blot analysis
Plasma samples were resolved on 10% SDS-PAGE gel, and
electro-transferred to nitrocellulose membrane (Bio-Rad
Laboratories, Hercules, CA, USA). In order to handle a
large number of samples that exceeded loading sites of a
gel, two or more gels were placed on a transfer membrane
to minimize experimental bias of western blots. Immunob-
loting analyses were performed as described previously
[12], using antibodies against neural cell adhesion molecule
L1 (CHL1; Atlas, Stockholm, Sweden), α1-acid glycopro-
tein 2 (ORM2; Proteintech Group Inc., Chicago, IL, USA),
monocyte differentiation antigen CD14 (CD14; Abcam,
Cambridge, MA, USA), BTD (GeneTex Inc., San Antonio,
TX, USA), and glutathione peroxidase 3 (GPX3; Abcam).
Analysis of gene expression microarray data
Large cohort tissue microarray datasets of breast cancer
patients analyzed by Human Genome U133A platform
(GPL96) were downloaded from the Gene Expression
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/
projects/geo/). The samples included 1,715 cases of biop-
sied breast cancer tissues (GSE1456, GSE2034, GSE2990,
GSE3494, GSE4922, GSE5364 and GSE11121) and 95
cases of laser-capture microdissected (LCM) breast cancer
tissues (GSE5847). The latter 95 samples were considered
to be positive controls for breast cancer, since the LCM
would be effective to get rid of contamination of normal tis-
sues or blood cells in the breast cancer biopsies. As refer-
ences, 39 microarray data of normal human breast tissues
analyzed by the same or upgrade version (GPL570) were
obtained from the GEO database. The obtained microarray
data were analyzed by the R-package 2.7.2 using an Affy
package and a gcRMA package to make normalization and
adjustments of the background and average intensities. The
average values of gene expression were calculated from
replicate probes. From the log2-transformed values of each
tumor sample, the log2 medians of included normal sam-
ples were subtracted to calculate a tumor-to-normal ratio
(fold change) conveniently.
Statistical analysis
Band intensities of Western blot images were quantified
using ImageQuant version 5.2. (GE Healthcare Biosci-
ences), and compared by Wilcoxon rank-sum test using
SPSS 12.0 (SPSS, Chicago, IL, USA) due to the small sam-
ple size. For the statistical analysis of gene expression data,
Wilcoxon rank-sum tests were performed with a 95% confi-
dence interval, as the sample size of breast cancer tissues
was greater than the size of normal controls and also the
two data sets had been collected independently from large
cohort breast cancer studies and standard human tissue
microarray studies.
Results
Profiling of breast cancer plasma proteins by ICAT
The ICAT method was introduced for profiling of differen-
tially expressed proteins in a set of pooled plasma samples
of breast cancer patients (n = 6, age = 36 - 59, cancer grade
= I - III) and age-matched normal healthy women (n = 6), as
shown in Table 1. Analyzing the ICAT-labeled tryptic pep-
tides by LC-MS/MS, a total of 155 proteins were confi-
dently identified by matching MS/MS data (646 unique
peptides) to the peptide sequences in human IPI database.
Of these, 121 proteins (78%) were identified by two or
more peptide matches, and 34 proteins (22%) were identi-
fied by single peptide match (Additional files 1 and 2). For
the identified proteins, spectral count (total number of pep-
tides) was plotted against peptide count (number of unique
peptides; Figure 1A). About 60% of the proteins were iden-
tified based on 1-4 unique peptides and only 42% were
identified based on 1-4 scans. The data were compared with
another set of ICAT experimental data reported by Aeber-
sold group in which tissue extract was analyzed [15].
Unlike the tissue extract data in which 75% of the proteins
were identified with single peptide match, only 22% pro-
teins were identified with single peptide match in our
plasma data (Figure 1B). In contrast, the number of proteins
identified by at least 5 peptides was similar: 62 for the tis-
sue extract and 63 for the plasma sample. For each peptide
count, spectral counts of plasma data distributed in wider
range than those of the tissue extract data. Therefore, total
number of identified proteins decreased in the currentKang et al. BMC Cancer 2010, 10:114
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plasma data as the number of single peptide match
decreased.
The ratios of differentially expressed proteins between
breast cancer (heavy isotope-labeled) and normal healthy
(light isotope labeled) plasma samples were calculated by
the XPRESS software. Logarithm of all heavy-to-light (H/
L) peptide ratios showed a maximum around zero (data not
shown). A normal quantile plot (QQ plot) in which the per-
centiles of the logarithms of H/L peptide ratios are plotted
against the percentiles from a normal distribution revealed
that the distribution of peptide ratios was deviated from
normality and had long tails at both ends (Figure 1C).
Heavy-tailed distribution was also observed in protein
ratios, indicating that the ICAT quantification data were
appropriate for detecting proteins having significant abun-
dance change between cancer and control. The apex of the
logarithm of all H/L protein ratios was also around zero
(Figure 1D). Thus, as shown in Additional file 3, most pro-
teins showed the H/L ratios near one. In contrast, 33 pro-
teins showed significantly different levels between plasmas
of breast cancer patients and normal healthy control by
more than 1.5 fold (Figure 1D). Of these proteins, 22 pro-
teins showed increased abundance, and 11 proteins showed
decreased abundance.
Confirmation of protein abundance difference by Western 
blot analysis
We next chose five proteins (CHL1, ORM2, CD14, BTD
and GPX3) among those that showed abundance change
and exploited Western blot for the follow-up studies (Table
2). The selection was mainly based on gene ontology data
about biological functions and disease relatedness of the
proteins as well as the availability and specificity of anti-
bodies commercially available. We first analyzed the
pooled plasma samples that had been used for ICAT experi-
ment. Of the five proteins tested, four except CHL1 dis-
played similar expression patterns with the ICAT ratios.
The level of ORM2 determined by Western blot increased
by 2.05 fold in the pooled plasma of breast cancer, whereas
the ICAT ratio was 1.85 relative to that of normal healthy
control. The BTD level, which decreased 2.3 fold in the
ICAT experiment, showed 1.96 fold decrease in the West-
ern blot analysis. The relative fold-changes of CD14 and
GPX3 were also similar in ICAT and Western blot results.
However, CHL1 showed reversed expression change,
which hindered further verification.
When the 12 samples were assayed individually for the
four biomarker candidates by Western blots, expression lev-
els of BTD and GPX3 were similar to those in the pooled
samples (Figure 2A). But, the results of CD14 and ORM2
were significantly different from the data for pooled sam-
ples (Figure 2B).
Gene expression of biomarker candidates in breast cancer 
tissues
To investigate changes in mRNA levels of BTD, CD14,
GPX3 and ORM2 in breast cancer tissues, a total of 1,849
microarray raw data (CEL files) was created by using
Affymetrix U133A (GPL96) and U133+2.0 (GPL570) plat-
forms were downloaded from the GEO database. Among
Table 1: Histopathological characteristics of breast cancers and normal healthy controls
Characteristics Discovery by ICAT & qualification Verification in a blinded set
Normal healthy control
No. cases 6 21
Age (median) 36-51(49.5) 17-49 (35)
Breast cancer
No. cases 6 21
Age (median) 36-51 (49.5) 36-78 (50)
Histological grade Grade 1 (2), Grade 2 (2), Grade 3 (2) Grade 0 (5), Grade 1 (4), Grade 2 (9), Grade 
3 (2), Grade 4 (1)
Tumor size T1 (3), T2 (3) T0 (6), T1 (6), T2 (8), T3 (1)
Lymph node status N0 (4), N2 (1), N3 (1) N0 (12), N1 (7), N2 (2)
Metastasis M0 (6) M0 (20), M1(1)
Estrogen receptor Negative (6) Negative (10), Positive (10)*
Progesterone receptor Negative (6) Negative (12), Positive (8)*
* Receptor type for one breast cancer patient was not determined.Kang et al. BMC Cancer 2010, 10:114
http://www.biomedcentral.com/1471-2407/10/114
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the four biomarker candidates, ORM2 showed significant
up-regulation in both biopsied and LCM breast cancer tis-
sues relative to normal controls (p < 0.001), whose log2-
transformed fold changes (log2FC) in the medians were
0.88 and 1.09, respectively (Figure 3). BTD displayed a sig-
nificant change only in the LCM samples (log2 FC = -0.86,
p = 0.003), but not in the biopsied samples (log2FC = -0.18,
p = 0.547). However, the medians of CD14 and GPX3 in
breast cancer patients did not have significant difference
with the normal controls (p > 0.05). The LCM microarray
data of BTD showed a greater mRNA fold change than the
biopsied tissue microarray data. This implies that the down-
regulated gene expression of BTD was strongly associated
with cancer cells.
Verification of BTD as potential breast cancer biomarker in 
plasma
In the initial stages of biomarker discovery using ICAT and
Western blot analysis, we confidently observed that BTD
and GPX3 were significantly down-regulated in breast can-
cer plasma compared to age-matched normal healthy con-
trol. For the clinical use, they must be verified in a larger
sample size. As shown in Table 1, a blinded set of plasmas
from 21 breast cancer patients (age = 36 - 78, cancer grade
= O - IV) and 21 normal healthy women (age = 17 - 49)
were tested to determine individual levels of BTD and
GPX3 by Western blots. Consistent with the preliminary
data, significant down-regulation of BTD was observed in
breast cancer plasma compared to the normal healthy con-
trol (p = 0.002; Figure 4A). The median value of BTD in
breast cancer was 1.9 fold lower than that of normal healthy
women (Figure 4B). BTD levels were significantly lower in
breast cancer grade I - IV than normal healthy controls, but
Figure 1 Profiling of breast cancer plasma proteins by ICAT. (A) Spectral count (total number of peptides) as a function of peptide count (number 
of unique peptides). Lower part is an enlarged view of spectral count ≤ 10 vs. peptide count. (B) Peptide count as a function of normalized rank of 
quantified proteins. Solid line: current data set, dashed line: tissue extract data set retrieved from [15] and reprocessed. (C) A quantile-quantile plot of 
the peptide quantification distribution. The percentiles of the logarithms of heavy-to-light peptide ratios are plotted against the percentiles from a 
normal distribution. (D) Profile of protein ratios. The ratios are log2-transformed. Bin size: 0.2.
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the BTD level of cancer grade O was not (p = 0.801; Figure
4C). Estrogen receptor status (p = 0.940) and progesterone
receptor status (p = 0.440) were not associated with the
plasma BTD levels (Figure 4D). Dividing the cancer
patients equally into two subgroups by the age, the differ-
ence between the BTD levels of younger and older groups
was not statistically significant (p = 0.888). Neither signifi-
cant difference was observed in case of the healthy control
(p = 0.481). The analysis of a receiver operating character-
istic (ROC) curve showed that the area under the ROC
curve (AUC) reached 0.78 (sensitivity = 47.6%; and speci-
ficity = 90.5%), suggesting it as a potential breast cancer
biomarker in plasma. In case of GPX3, however, there was
no significant difference between the medians of breast
cancer and normal healthy women (p = 0.678; Figure 4E),
indicating that GPX3 cannot critically discriminate breast
cancer from normal healthy control. Taking these results
Table 2: List of proteins and their abundance ratios between cancer and control
Uniprot* Gene name Abundance ratio (cancer/control)
ICAT
(N = 2)†
Western blot
(N = 2)†
Western blot
(n = 12)‡
Western blot
(n = 42)‡
O00533 CHL1 2.05 0.66
P19652 ORM2 1.85 2.05 1.01
P08571 CD14 1.69 1.29 1.78
P43251 BTD 0.44 0.51 0.43 0.52
P22352 GPX3 0.37 0.53 0.42 1
*Uniprot, protein accession number in the SWISS-PROT/TrEMBL database.
†N denotes pooled plasma samples of breast cancer (n = 6) and normal healthy control (n = 6)
‡n, the number of individual samples.
Figure 2 Western blot analysis of ORM2, CD14, BTD and GPX3. (A) Western blot analysis was performed for the plasmas of 6 breast cancer pa-
tients and age-matched 6 normal healthy women that had been previously used for ICAT experiment. (B) Western blot images were quantified by 
densitometric scanning and plotted. Lines denote the average of intensity values.
A non-cancer breast cancer non-cancer breast cancer non cancer breast cancer non cancer breast cancer
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into account together, BTD is considered to be a novel
potential biomarker for breast cancer.
Discussion
In this study we discovered serum BTD as a potential breast
cancer biomarker through the biomarker development pipe-
line encompassing mass spectrometry based screening and
independent downstream immunoblot assays. Biomarker
candidates discovered by ICAT analysis of plasmas from 6
breast cancer patients and 6 age-matched normal healthy
controls were examined by Western blot in the same sample
set. The two candidates, BTD and GPX3, confirmed by this
approach were next tested with immunoblot assay in a
blinded set of breast cancer and control to ascertain the
markers ability to differentiate the two groups.
The ICAT method applied here for the screening of differ-
entially expressed proteins has low-throughput and is not
suitable for a large number of samples. Therefore, a sample
pooling strategy was employed to overcome this drawback.
Although pooling reduces the expense of costly assays,
nevertheless their still remains a possibility to obtain biased
quantification result stemming from individual variations,
which necessitates an independent downstream assay in
individual samples. In the immunoblot assays after the
ICAT discovery phase, we had to drop some candidate
markers like GPX3. Our results suggest that the sample
pooling strategy has both advantages and disadvantages.
We adapted immunodepletion of top six high-abundance
proteins to dig deep into low abundance proteins since
plasma proteins are present over a wide dynamic range in
concentration. This antibody-based separation system has
demonstrated high efficiency to remove the specifically tar-
geted proteins as well as both reproducibility and selectivity
[16-19]. Actually, it was effective in our study enough to
detect protein that exist at about a few μg/ml in plasma such
as L-selectin [20].
Differential profiling by ICAT method enabled us to iden-
tify and quantify a total of 155 plasma proteins. The num-
ber was much smaller than that of proteins identified by the
same method with tissue extract proteome [15], which was
accounted for by the small number of the proteins identified
based on single peptide match. On the contrary, spectral
Figure 3 The mRNA levels of ORM2, CD14, BTD and GPX3. Box-plots of log2-transformed average fold changes (log2avFC) of the gene expression 
levels of BTD, CD14, GPX3 and ORM2 in breast cancer tissues (total n = 1,810) relative to the normal healthy tissues (n = 39). Statistically significant 
difference between breast cancer and normal tissues were tested by Wilcoxon tests. Breast cancer tissues were categorized into two groups of breast 
biopsy samples (Biopsy, n = 1,715) and laser capture microdissected samples (LCM, n = 95).Kang et al. BMC Cancer 2010, 10:114
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counts for each peptide count were distributed more widely:
for example, spectral counts ranged from 2 to 23 for the
proteins identified with two unique peptides. This is clearly
due to the concentration depth of plasma proteome. Our
result indeed covered 4 orders of magnitude from the low-
est L-selectin at 0.67 μg/ml to the highest α-2-macroglobu-
lin at 1.8 mg/ml [20]. The lower detection limit was similar
to another study performed on plasma proteome [21],
which indicated that ICAT analysis for immunodepleted
plasma samples is effective for biomarker discovery
medium-abundance protein. Comparing current plasma
proteome list with those of our previous studies [11,12] and
a recent report related to multiplex serum biomarker [22],
several proteins, such as transthyretin, vitamin D-binding
protein, and endorepellin were commonly identified. How-
ever, in the current study, these proteins showed little
change among breast cancer patients and normal healthy
controls (Additional file 1), and hence were excluded from
further analysis. This is due to the difference in sample
sources and in the screening method. 2DE or SELDI-TOF
was used in the previous studies while we adapted ICAT
strategy in this study. As mentioned earlier, protein quanti-
fication by ICAT is based only on cysteine containing pep-
tide whereas 2DE reflects whole protein features including
proteolytic processing. In addition, the previous study also
could not draw decisive conclusion about discriminatory
power of transthyretin and vitamin D-binding protein [22].
In case of endorepellin, we discovered LG3 fragment of the
protein as a biomarker in the previous study [12]. In con-
trast, the single ICAT peptide matched to endorepellin cov-
ered other part than the LG3 fragment in the current study.
Moreover, common proteins such as heptoglobin, serum
albumin and transferrin were detected not due to their dif-
ferential regulation in breast cancer but due to incomplete
depletion of these proteins from plasma during immunoaf-
finity chromatography (in this study) or incomplete
removal of blood vessels in the preparation of breast tissues
(in the previous study [11]). Therefore, such proteins were
Figure 4 Western blot analysis of BTD and GPX3 in a blinded set of plasmas. (A, E) Western blot images of BTD and GPX3 in a blinded set of 
plasmas from 21 breast cancer and 21 normal healthy women. (B, F) Box-plots (left panels) and receiver operating characteristic (ROC) curves (right 
panels). (C) BTD levels according to breast cancer grade. (D) BTD levels according to estrogen receptor (ER) and progesterone receptor (PR) status.
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not put into the next qualification phase of this study, while
the proteins chosen for qualification were seemingly novel
proteins discovered in relation to breast cancer.
Among the proteins showing differential level between
breast cancer patients and normal healthy women, we chose
five proteins for further verification. In this experimental
flow, 4 biomarker candidates including ORM2, CD14, BTD
and GPX3 showed relatively similar quantification results
both in ICAT and Western blot. In case of CHL1, we
observed an inconsistency between two quantification
results (Table 2). According to ICAT result, CHL1 was
quantified based on a single peptide (LHMLELHCESK;
Additional file 2) in which the methionine residue had for-
merly been oxidized. Methionine oxidation occurs fre-
quently during sample preparation and handling. Therefore,
it seems inappropriate to quantify proteins based on a single
oxidized peptide. Increased level of ORM2 [23] and CD14
[24] or down regulation of GPX3 [25] appears to be reason-
able when interpreted in relation to their biological func-
tions. However, we could not confirm their ICAT fold
changes in the subsequent verification steps. It is likely that
expression levels of ORM2, CD14 and GPX3 vary with age
or with other factors that are currently unknown. Other pos-
sibility like stochastic variation cannot be excluded. Inter-
estingly, the mRNA level of BTD in breast cancer tissue
also changed compared to normal breast tissues. There is no
evidence and it is unlikely that expression change of BTD
in breast cancer tissues affect their levels in plasma. There-
fore, the abundance change of BTD observed in the plas-
mas of breast cancer patients need not necessarily be the
same as the abundance change of tissue mRNA. Neverthe-
less, it is worthy investing BTD for their potential use as
tissue biomarkers in future study.
Among five candidates, BTD subsisted until the last step
of verification of the biomarker pipeline. BTD is known to
catalyze the release and recycling of endogenous biotin
[26]. It is known to be secreted into blood circulation [27],
and is highly active in the serum, liver, kidney and adrenal
glands. Its deficiency results in various diseases such as sei-
zures, hypotonia, hyperammonemia, and so forth [28]. We
first reported here that its level was consistently down-regu-
lated in breast cancer plasma. It is, yet, difficult to explain
how BTD is down-regulated in breast cancer plasma. Inter-
estingly, transcriptional levels of BTD in breast cancer tis-
sues were also down-regulated. So, it merits further studies
to elucidate down-regulation of BTD in relation to the
behavior of breast cancer cells. Despite many uncertainties
in the cellular and molecular mechanism of BTD, it is
apparent from our results that BTD is down-regulated in
breast cancer plasma. It will be useful and applicable for
clinical use alone or in combination with other biomarkers
in detecting breast cancer by less invasive techniques using
plasma samples.
Conclusion
Blood is a containment of communicating cells, tissues and
organs in human body. Physiological change due to occur-
rence of a certain disease will be reflected to the blood pro-
teome. An increased or decreased protein in the plasma can
be considered to be a serological biomarker for the disease.
In the present work we adapted comparative proteomic
study using ICAT labeling and tandem mass spectrometry
in search of new serological biomarkers for breast cancer.
Among 33 proteins that showed differential abundance
level between plasmas of breast cancer patients and normal
healthy controls, BTD was shown to be decreased in breast
cancer plasma. BTD successfully discriminated breast can-
cer patients from normal healthy controls in a blinded set of
42 cases. Our study suggests a diagnostic value of serum
BTD for the detection of breast cancer.
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